NK2 receptors mediate tachykinin-induced contractions of rat uterus during the oestrous cycle.
We examined tachykinin-induced contractions of uteri from rats during the oestrous cycle. The potencies of substance P, neurokinin A, neurokinin B and the tachykinin NK2 receptor-selective agonist, [Lys5, MeLeu9, Nle10] neurokinin A-(4-10), and of the non-peptide tachykinin NK1, NK2 and NK3 receptor antagonists (S)1-[2-[3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenylacetyl)pip eridin-3-yl]ethyl]-4phenyl-1-azonia-bicyclo[2.2.2]octane (SR 140333), (S)-N-methyl-N [4-(4-acetylamino-4-phenylpiperidino)-2-(3,4-dichlorophenyl)butyl]benzam ide (SR 48968) and (S)-(N)-(1-(3-(1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl)prop yl)-4-phenylpiperidin-4-yl)-N-methylacetamide (SR 142801), were examined. The relative agonist potencies, i.e., [Lys5, MeLeu9, Nle10] neurokinin A-(4-10) > or = neurokinin A > neurokinin B > or = substance P were similar in preparations from rats in dioestrus/metoestrus and those in proestrus/oestrus. Apparent pK(B) values for SR 48968 versus neurokinin A and [Lys5, MeLeu9, Nle10] neurokinin A-(4-10), were 9.9 and 9.2, respectively, indicating activation of an NK2 receptor. SR 140333 (10 nM) produced only a small rightward shift of the log concentration-response curve to substance P. SR 48968 (3 nM), but not SR 142801 (100-300 nM) reduced the effect of neurokinin B. These data indicate that in the rat tachykinin-induced contractions of the uteri during the oestrous cycle are mediated primarily by tachykinin NK2 receptors, and that fluctuations in ovarian hormonal levels during the oestrous cycle have little influence on the uterine response to tachykinins.
Moodley
N
N
Department of Pharmacology, Monash University, Clayton, Victoria, Australia.
Lau
W A
WA
Pennefather
J N
JN
Story
M E
ME
Fisher
L
L
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001549:Benzamides / Q000737:chemistry / Q000494:pharmacology; D004031:Diestrus / Q000502:physiology; D004971:Estrus / Q000502:physiology*; D005260:Female; D016210:Methacholine Chloride / Q000494:pharmacology; D015288:Neurokinin A / Q000494:pharmacology; D064729:Neurokinin-1 Receptor Antagonists; D010455:Peptides; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology; D011359:Proestrus / Q000502:physiology; D011812:Quinuclidines / Q000737:chemistry / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000819:agonists; D018041:Receptors, Neurokinin-2 / Q000819:agonists / Q000037:antagonists & inhibitors / Q000502:physiology*; D018042:Receptors, Neurokinin-3 / Q000819:agonists / Q000037:antagonists & inhibitors; D015320:Tachykinins / Q000494:pharmacology*; D014590:Uterine Contraction / Q000187:drug effects / Q000502:physiology*
D000900:Anti-Bacterial Agents; D001549:Benzamides; D064729:Neurokinin-1 Receptor Antagonists; D010455:Peptides; D010880:Piperidines; D011812:Quinuclidines; D018040:Receptors, Neurokinin-1; D018041:Receptors, Neurokinin-2; D018042:Receptors, Neurokinin-3; D015320:Tachykinins; D016210:Methacholine Chloride; C085215:SR 140333; C016977:amastatin; C073839:SR 48968; D015288:Neurokinin A; C091554:SR 142801